Dashboard
1
Poor Management Efficiency with a low ROCE of 6.47%
- The company has been able to generate a Return on Capital Employed (avg) of 6.47% signifying low profitability per unit of total capital (equity and debt)
2
Flat results in Mar 25
3
With ROE of 4.95%, it has a expensive valuation with a 3.98 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,852 Million (Small Cap)
80.00
NA
0.00%
-0.27
4.95%
3.98
Revenue and Profits:
Net Sales:
76 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.54%
0%
17.54%
6 Months
17.17%
0%
17.17%
1 Year
-12.05%
0%
-12.05%
2 Years
-1.86%
0%
-1.86%
3 Years
10.0%
0%
10.0%
4 Years
-4.29%
0%
-4.29%
5 Years
47.4%
0%
47.4%
Guangdong Jiaying Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.37%
EBIT Growth (5y)
54.66%
EBIT to Interest (avg)
26.49
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.37
Sales to Capital Employed (avg)
0.66
Tax Ratio
17.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.47%
ROE (avg)
3.75%
Valuation key factors
Factor
Value
P/E Ratio
80
Industry P/E
Price to Book Value
3.98
EV to EBIT
64.83
EV to EBITDA
42.54
EV to Capital Employed
5.12
EV to Sales
6.85
PEG Ratio
1.19
Dividend Yield
NA
ROCE (Latest)
7.89%
ROE (Latest)
4.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
75.90
84.20
-9.86%
Operating Profit (PBDIT) excl Other Income
9.00
2.60
246.15%
Interest
0.00
0.00
Exceptional Items
0.10
0.20
-50.00%
Consolidate Net Profit
4.70
0.50
840.00%
Operating Profit Margin (Excl OI)
41.00%
-28.30%
6.93%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -9.86% vs -33.49% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 840.00% vs -91.80% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
369.00
524.20
-29.61%
Operating Profit (PBDIT) excl Other Income
40.50
59.80
-32.27%
Interest
0.00
0.00
Exceptional Items
-0.30
0.60
-150.00%
Consolidate Net Profit
20.60
34.30
-39.94%
Operating Profit Margin (Excl OI)
56.30%
67.90%
-1.16%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -29.61% vs -19.18% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -39.94% vs -21.87% in Dec 2023
About Guangdong Jiaying Pharmaceutical Co., Ltd. 
Guangdong Jiaying Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






